Ventyx Biosciences, Inc.
VTYX
$7.94
-$1.44-15.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.78% | -8.22% | -7.57% | -2.42% | -0.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.85% | -29.81% | -33.99% | -28.63% | -15.21% |
| Operating Income | 29.85% | 29.81% | 33.99% | 28.63% | 15.21% |
| Income Before Tax | 30.10% | 30.52% | 35.62% | 29.97% | 15.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.10% | 30.52% | 35.62% | 29.97% | 15.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.10% | 30.52% | 35.62% | 29.97% | 15.93% |
| EBIT | 29.85% | 29.81% | 33.99% | 28.63% | 15.21% |
| EBITDA | 29.91% | 29.88% | 34.07% | 28.70% | 15.28% |
| EPS Basic | 36.64% | 39.76% | 45.97% | 39.59% | 24.22% |
| Normalized Basic EPS | 36.65% | 39.75% | 45.96% | 39.58% | 24.22% |
| EPS Diluted | 36.64% | 39.76% | 45.97% | 39.59% | 24.22% |
| Normalized Diluted EPS | 36.65% | 39.75% | 45.96% | 39.58% | 24.22% |
| Average Basic Shares Outstanding | 8.51% | 13.37% | 18.81% | 16.96% | 13.08% |
| Average Diluted Shares Outstanding | 8.51% | 13.37% | 18.81% | 16.96% | 13.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |